Emergent BioSolutions Inc (EBS)
5.55
+0.28
(+5.31%)
USD |
NYSE |
May 17, 16:00
5.55
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Research and Development Expense (Quarterly): 15.10M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 15.10M |
| December 31, 2023 | 29.40M |
| September 30, 2023 | 15.30M |
| June 30, 2023 | 26.00M |
| March 31, 2023 | 40.70M |
| December 31, 2022 | 47.00M |
| September 30, 2022 | 42.20M |
| June 30, 2022 | 49.80M |
| March 31, 2022 | 46.40M |
| December 31, 2021 | 84.20M |
| September 30, 2021 | 49.60M |
| June 30, 2021 | 48.90M |
| March 31, 2021 | 52.50M |
| December 31, 2020 | 62.90M |
| September 30, 2020 | 84.40M |
| June 30, 2020 | 47.90M |
| March 31, 2020 | 42.70M |
| December 31, 2019 | 62.80M |
| September 30, 2019 | 53.40M |
| June 30, 2019 | 63.90M |
| March 31, 2019 | 46.10M |
| December 31, 2018 | 52.00M |
| September 30, 2018 | 37.00M |
| June 30, 2018 | 24.70M |
| March 31, 2018 | 29.10M |
| Date | Value |
|---|---|
| December 31, 2017 | 28.51M |
| September 30, 2017 | 22.66M |
| June 30, 2017 | 25.75M |
| March 31, 2017 | 20.48M |
| December 31, 2016 | 25.73M |
| September 30, 2016 | 27.19M |
| June 30, 2016 | 27.89M |
| March 31, 2016 | 26.09M |
| December 31, 2015 | 25.35M |
| September 30, 2015 | 34.18M |
| June 30, 2015 | 40.94M |
| March 31, 2015 | 38.70M |
| December 31, 2014 | -7.143M |
| September 30, 2014 | 44.21M |
| June 30, 2014 | 37.40M |
| March 31, 2014 | 30.26M |
| December 31, 2013 | 29.99M |
| September 30, 2013 | 28.94M |
| June 30, 2013 | 30.28M |
| March 31, 2013 | 30.72M |
| December 31, 2012 | 35.94M |
| September 30, 2012 | 27.39M |
| June 30, 2012 | 30.64M |
| March 31, 2012 | 26.25M |
| December 31, 2011 | 29.38M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.10M
Minimum
Mar 2024
84.40M
Maximum
Sep 2020
48.26M
Average
48.40M
Median
Research and Development Expense (Quarterly) Benchmarks
| Avid Bioservices Inc | -- |
| Viking Therapeutics Inc | 24.10M |
| FibroGen Inc | 38.39M |
| Avinger Inc | 1.152M |
| RAPT Therapeutics Inc | 24.78M |